Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 10/20 | 0.52 |
| ▸ | PSMB8 | P28062 | 7/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.52 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.49 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.49 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15075885 | 1.00 | PSMB5 (0.52) | PSMB5PSMB8CTRB1PSMB9PSMB6 | |
| SCHEMBL15058611 | 0.93 | MME (0.49) | PSMB5PSMB8CTRB1PSMB9PSMB6 | |
| SCHEMBL15075904 | 0.92 | MME (0.48) | PSMB5PSMB8CTRB1PSMB9PSMB6 | |
| SCHEMBL15075984 | 0.92 | MME (0.48) | PSMB5PSMB8CTRB1PSMB9PSMB6 | |
| SCHEMBL15075889 | 0.88 | PSMB5 (0.52) | PSMB5PSMB8 | |
| SCHEMBL15058365 | 0.88 | PSMB5 (0.48) | PSMB5PSMB8CTRB1PSMB9PSMB6 | |
| SCHEMBL19034175 | 0.83 | MME (0.45) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL15075814 | 0.83 | CAPN1 (0.57) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL15076012 | 0.83 | CAPN1 (0.57) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL23131356 | 0.81 | PSMB5 (0.48) | PSMB5PSMB8CTRB1PSMB9PSMB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793900-B1 | ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS | ARES TRADING SA (CH) | 2018-08-22 | — | — | EP | disclosed |
| US-9688702-B2 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING (CH) | 2017-06-27 | — | — | US | disclosed |
| US-9688702-B2 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING (CH) | 2017-06-27 | — | — | US | disclosed |
| US-9688702-B2 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | ARES TRADING SA (CH) | 2014-12-11 | — | — | US | disclosed |
| EP-2793900-A1 | ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS | Ares Trading S.A. (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013092979-A1 | ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS | ARES TRADING S.A. (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092979-A1 | ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS | ARES TRADING S.A. (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364396-A1 | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors | PSMB7, PSMA7, PSMB1 | PSMB5 5/4885PSMB8 10/4885CTRB1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.